ライフサイエンスコーパス: 2-amino-5-phosphonovaleric acid

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 blocked by the NMDA receptor antagonist d,l-2-amino-5-phosphonovaleric acid.

2 locomotor-like activity that was blocked by 2-amino-5-phosphonovaleric acid.

3 to the selective NMDA receptor antagonist 5-2-amino-5-phosphonovaleric acid (20 microM) and was mark

4 o-exposure to the NMDA receptor antagonist D-2-amino-5-phosphonovaleric acid (20 microM) prevented to

5 Finally, microinjection of 2-amino-5-phosphonovaleric acid (5 ng) into the frontal

6 2-Amino-5-phosphonovaleric acid, an inhibitor of N'-meth

7 with the glutamate receptor antagonists (DL-2-amino-5-phosphonovaleric acid and 6-cyano-7-nitroquino

8 This residual potential was abolished by 2-amino-5-phosphonovaleric acid and 6-cyano-7-nitroquino

9 The effect was blocked by 2-amino-5-phosphonovaleric acid and 7-chloro-kynurenic a

10 a facilitation that is partially blocked by 2-amino-5-phosphonovaleric acid and by injection of 1,2-

11 could be blocked by NMDA-receptor antagonist 2-amino-5-phosphonovaleric acid and by NO synthase inhib

12 containing 100 microM caged glutamate, APV (2-amino-5-phosphonovaleric acid), and high divalent cati

13 NMDA receptor antagonist, DL-2-Amino-5-Phosphonovaleric acid (AP-5), blocked the NMDA

14 s blocked by the NMDA receptor antagonist DL-2-amino-5-phosphonovaleric acid (AP5).

15 ments were done in the presence of 50 microM 2-amino-5-phosphonovaleric acid (APV) and 20 microM 6-cy

16 insensitive to the competitive antagonists D-2-amino-5-phosphonovaleric acid (APV) and 7-Cl-kynurenic

17 infusions of the NMDA receptor antagonist DL-2-amino-5-phosphonovaleric acid (APV) completely blocked

18 rforant path plasticity can be attenuated by 2-amino-5-phosphonovaleric acid (APV) infusions, whereas

19 The glutamate receptor antagonists, D,L-2-amino-5-phosphonovaleric acid (APV) or 6,7-dinitroquin

20 roquinoxaline-2,3-dione (CNQX) and 50 microM 2-amino-5-phosphonovaleric acid (APV)) were dramatically

21 s addressed by infusing the rat BLA with d,l-2-amino-5-phosphonovaleric acid (APV), a competitive NMD

22 not blocked by the NMDA receptor antagonist 2-amino-5-phosphonovaleric acid (APV), but were eliminat

23 The currents were reversibly inhibited by DL-2-amino-5-phosphonovaleric acid (APV).

24 ever, microinjection of the NMDA agonists DL-2-amino-5-phosphonovaleric acid (APV; 50 mM) or DL-2-ami

25 ment with the NMDA receptor antagonist d-(-)-2-amino-5-phosphonovaleric acid (d-AP-5) disrupted the t

26 D-aspartate (NMDA) receptor antagonist D-(-)-2-amino-5-phosphonovaleric acid (D-APV) as well as the b

27 effective in the continuous presence of D(-)-2-amino-5-phosphonovaleric acid (D-APV), an NMDA-site an

28 pplication of the NMDA receptor antagonist D-2-amino-5-phosphonovaleric acid (D-APV).

29 anner and by the NMDA-site antagonist, D-(-)-2-amino-5-phosphonovaleric acid (D-APV).

30 e-cell patch electrodes in the presence of D-2-amino-5-phosphonovaleric acid (D-APV, 50 microM), 6-cy

31 Another competitive antagonist, 2-amino-5-phosphonovaleric acid, had similar effects.

32 s reduced, but not completely blocked, by DL-2-amino-5-phosphonovaleric acid, implying that some othe

33 e N-methyl-D-aspartate receptor antagonist D-2-amino-5-phosphonovaleric acid, indicating that a long-

34 tely blocked by the NMDA receptor antagonist 2-amino-5-phosphonovaleric acid, indicating that D1-like

35 ing competitive antagonists kynurenate and L-2-amino-5-phosphonovaleric acid (LAPV) inhibited fast an

36 eptors were blocked by bath application of D-2-amino-5-phosphonovaleric acid, LTD was abolished or st

37 ion, because it is blocked by infusion of dl-2-amino-5-phosphonovaleric acid or 6,7-dinitroquinoxalin

38 0 Hz tetanus was blocked by 50-100 microM DL-2-amino-5-phosphonovaleric acid, suggesting that N-methy

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。